PF-06952229 |
رقم الكتالوجGC39636 |
PF-06952229 هو مثبط TGFbR1 فعال وانتقائي وفعال عن طريق الفميرتبط PF-06952229 على وجه التحديد بـ TGFbR1 ويمنع نقل الإشارة بوساطة TGFbR1PF-06952229 هو عامل واعد لمضادات الأورام للأورام الصلبة ، وخاصة سرطان الثدي النقيلي
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1801333-55-0
Sample solution is provided at 25 µL, 10mM.
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer[1].
[1]. Flavia Mercer Pernasetti, et al. Combinations of tgfb inhibitors and cdk inhibitors for the treatment of breast cancer. Patent WO2020058820A1.
Average Rating: 5
(Based on Reviews and 21 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *